Interestingly, the O-GlcNAcase inhibitor promoted ACSS2 Ser-267 phosphorylation in glioblastoma cells, without affecting normal astrocytes [35], highlighting its potential for further application in glioblastoma therapy. This evidence concerns the gene OGA and glioblastoma.